GENELUX CORPORATION Debt Securities, Available-for-sale, Unrealized Gain
GENELUX CORPORATION (GNLX) reported Debt Securities, Available-for-sale, Unrealized Gain of $6.00 thousand for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-08-13
- GENELUX CORPORATION debt securities, available-for-sale, unrealized gain for the quarter ending 2025-12-31 was -$1.00K.
- GENELUX CORPORATION debt securities, available-for-sale, unrealized gain for the quarter ending 2025-09-30 was $1.00K.
- GENELUX CORPORATION debt securities, available-for-sale, unrealized gain for the quarter ending 2025-06-30 was -$21.00K.
- GENELUX CORPORATION debt securities, available-for-sale, unrealized gain for the quarter ending 2025-03-31 was $27.00K.
- GENELUX CORPORATION debt securities, available-for-sale, unrealized gain for fiscal 2024 was $62.00K, a 416.67% increase from fiscal 2023.
- GENELUX CORPORATION debt securities, available-for-sale, unrealized gain for fiscal 2023 was $12.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$1.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | -$21.00K derived: sum of 3 quarters · filed 2026-08-13 | $6.00K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$20.00K derived: sum of 2 quarters · filed 2025-11-05 | $7.00K 10-Q · filed 2025-11-05 | -$52.00K derived: sum of 4 quarters · filed 2026-03-19 |
| 2025-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $6.00K 10-Q · filed 2025-08-07 | -$53.00K derived: sum of 3 quarters · filed 2026-03-19 | |
| 2025-03-31 | $27.00K 10-Q · filed 2025-05-06 | -$32.00K derived: sum of 2 quarters · filed 2026-03-19 | ||
| 2024-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $62.00K 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $121.00K 10-Q · filed 2024-11-14 | |||
| 2023-12-31 | $12.00K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |